Abstract |
Cefmenoxime (CMX) was intravenously administered to 106 patients with complicated urinary tract infection at a daily dose of 2-4 g for 5 days. An excellent response in overall clinical efficacy was seen in 15 cases (18.3%), a moderate response in 46 cases (56.1%) and poor response in 21 cases (25.6%). Pyuria was cleared in 20 cases (24.4%), decreased in 22 cases (26.8%) and unchanged in 40 cases (48.8%). Bacteriuria was eliminated in 41 cases (50.0%), decreased in 17 cases (20.7%), relapsed in 7 cases (8.5%) and unchanged in 17 cases (20.7%). Bacteriologically, 74 (76.8%) of the 95 strains isolated were eradicated by CMX, and 22 (23.2%) persisted. Side effects were observed in 3 ( abdominal pain, diarrhea and elevation of trans amylase) of the 106 cases. Judging from the above results, CMX is considered to be a useful drug in the treatment of complicated urinary tract infections.
|
Authors | Y Minami, S Kanda, R Matsuo, H Sakai, H Kamemoto, A Hisamatsu, N Maruta, A Johdai, H Shimomae, Y Watanabe |
Journal | Hinyokika kiyo. Acta urologica Japonica
(Hinyokika Kiyo)
Vol. 31
Issue 6
Pg. 1077-84
(Jun 1985)
ISSN: 0018-1994 [Print] Japan |
PMID | 3864365
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Cefmenoxime
- Cefotaxime
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Drug Evaluation
- Female
- Humans
- Infusions, Parenteral
- Injections, Intravenous
- Male
- Middle Aged
- Urinary Tract Infections
(drug therapy, microbiology)
|